胺碘酮联合普伐他汀治疗非瓣膜性阵发性心房颤动的临床观察

Amiodarone Combined with Pravastatin in Treatment of Non-vavular Paroxysmal Atrial Fibrillation:A Clinical Study

目的探讨胺碘酮联合普伐他汀治疗非瓣膜性阵发性心房颤动的疗效。方法将97例患者随机分为治疗组(47例)和对照组(50例),对照组服用胺碘酮,治疗组服用胺碘酮+普伐他汀,观察两组治疗前后心房颤动发作次数、持续时间、血清C-反应蛋白(CRP)水平及左房内径变化。结果两组经治疗后心房颤动发作次数及持续时间较治疗前明显减少(P<0.05),治疗组CRP及左房内径较治疗前明显改善,与对照组治疗后比较也有统计学意义(P<0.05)。结论胺碘酮联合普伐他汀能有效预防阵发性心房颤动复发,其机制与降低血清中炎症因子水平有关。

Objective To study the effect of amiodarone combined with pravastatin for non-valvular paroxysmal atrial fibrillation.Methods Ninty-seven cases were randomly divided into treatment group （n=47） and control group（n=50）.The control group was treated with amiodarone, and the treatment group with amiodarone plus pravastatin.The frequency of atrial fibrillation occurrence and the duration of atrial fibrillation,the left atrial diameter and C-reactive protein in the two groups were detected before and after treatment.Results The frequency of atrial fibrillation occurrence and the duration of atrial fibrillation after treatment were significantly decreased in the two groups （P0.05）.After treatment, the left atrial diameter and C-reactive protein in the treatment group were significantly lower than those in the control group （P0.05）.Conclusion Amiodarone combined with pravastatin can reduce the recurrence of paroxysmal atrial fibrillation,which is related to the anti-inflammation of pravastatin.